Our panel of breast cancer PDX with different HER2 expression score and amplification pattern was used to study the effects of two drugs targeting HER2 with different mechanisms, the humanized monoclonal antibody trastuzumab and the small irreversible pan-HER tyrosine kinase inhibitor neratinib. This evidence concerns the gene ERBB2 and breast cancer.